A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
About This Trial
- This study looks at existing medical records to learn how adults with advanced prostate cancer respond to treatments in everyday clinical practice.
- It focuses on patients whose cancer has spread and who have already received hormone therapy, chemotherapy, and a targeted radiation therapy.
- Because this is an observational study that reviews health data, it does not involve taking a new medication or attending extra clinic visits.
- Instead, the goal is to help doctors better understand which treatment approaches work best after these standard therapies have been completed.
More Information
- The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice.
- This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Who Can Enroll
- Age Range: 18 - 115 years
- Gender: Male
- Who This Trial is For: This study looks at existing medical records to learn how adults with advanced prostate cancer respond to treatments in everyday clinical practice.
Study Details
- Start Date: June 30, 2026
- Lead Sponsor: Novartis Pharmaceuticals
Full Eligibility Criteria
Inclusion Criteria
- Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
- Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
- Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
- Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
- Age ≥18 years at index.
Exclusion Criteria
• None.